- Home
- PVLA
as 03-28-2025 4:00pm EST
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 308.2M | IPO Year: | N/A |
| Target Price: | $43.50 | AVG Volume (30 days): | 90.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.20 - $29.27 | Next Earning Date: | 05-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Palvella Therapeutics Inc. Common Stock News
PVLA Breaking Stock News: Dive into PVLA Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
Simply Wall St.
13 days ago
Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well
Insider Monkey
a month ago
Why Palvella Therapeutics, Inc. (PVLA) is Skyrocketing So Far in 2025
GlobeNewswire
a month ago
Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
TipRanks
a month ago
Palantir initiated, Roku upgraded: Wall Street’s top analyst calls
GlobeNewswire
2 months ago
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
GlobeNewswire
3 months ago
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
GlobeNewswire
3 months ago
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
Compare PVLA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PVLA Palvella Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.